Aptevo Therapeutics Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics or view top-rated stocks.

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Aptevo Therapeutics.

Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($2.05) by $0.10. The biotechnology company earned $1.46 million during the quarter, compared to analysts' expectations of $0.49 million.
View Aptevo Therapeutics' earnings history.

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APVO shares have increased by 7,264.3% and is now trading at $30.93.
View which stocks have been most impacted by COVID-19.

1 equities research analysts have issued 1-year price objectives for Aptevo Therapeutics' shares. Their forecasts range from $32.00 to $32.00. On average, they expect Aptevo Therapeutics' stock price to reach $32.00 in the next year. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for Aptevo Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aptevo Therapeutics include Molecular Templates (MTEM), AnaptysBio (ANAB), SIGA Technologies (SIGA), Urovant Sciences (UROV), Basilea Pharmaceutica (BPMUF), Inventiva (IVA), Marinus Pharmaceuticals (MRNS), Akebia Therapeutics (AKBA), Amryt Pharma (AMYT), Neoleukin Therapeutics (NLTX), Bicycle Therapeutics (BCYC), Altimmune (ALT), Wave Life Sciences (WVE), Crinetics Pharmaceuticals (CRNX) and Viking Therapeutics (VKTX).
View all of APVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.81%), BlackRock Inc. (1.33%), Ghost Tree Capital LLC (1.14%), Alyeska Investment Group L.P. (1.13%), Alyeska Investment Group L.P. (1.13%) and Stonepine Capital Management LLC (0.42%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Kevin C Tang, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi.
View institutional ownership trends for Aptevo Therapeutics.

APVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Aptevo Therapeutics or view top insider-selling stocks.

APVO stock was acquired by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., BlackRock Inc., Stonepine Capital Management LLC, Dynamic Technology Lab Private Ltd, Northern Trust Corp, and Pura Vida Investments LLC. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Kevin C Tang, Marvin L White, Randy Joe Maddux, and Zsolt Harsanyi.
View insider buying and selling activity for Aptevo Therapeutics or or view top insider-buying stocks.

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APVO stock can currently be purchased for approximately $30.93.

Aptevo Therapeutics has a market capitalization of $135.44 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis.

Aptevo Therapeutics employs 80 workers across the globe.

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

Aptevo Therapeutics is headquartered at 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]